Market news

ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal™ technology, today announced its planned participation in two upcoming investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth ConferenceSeptember 10, 2026Metropolitan ClubNew York, New YorkH.C. Wainwright 28th Annual Global

Detailed price information for Vivani Medical Inc (VANI-Q) from The Globe and Mail including charting and trades.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal™ technology Completion of the Cortigent-ClearOne merger into Cortigent Holdings and initiation of trading on the Nasdaq exchange under ticker symbol CRGT an

Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1™ trial is a Phase 1, randomized, controlled clinical trial design to characterize the safety, tolerability, and pharmacokinetics of NPM-139 including a Wegovy® (semaglutide injection) group. Top-line data from the 20-participant trial is expected in November of 2026. ALAMEDA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) today an

Vivani Medical (NASDAQ:VANI) said it is preparing to begin human testing of its semaglutide implant in August and highlighted a recently announced agreement with Novo Nordisk to evaluate the company’s implant technology. Adam Mendelsohn, co-founder, CEO and director of Vivani Medical, said the past

Vivani says its implant delivers medication steadily over long periods of time.

ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or twice-yearly administration, today announced that it will present at the Emerging Growth Conference on July 15, 2026. Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive presentation at the Emerging Growth Conference. V

Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.

Vivani Medical’s new agreement gives Novo Nordisk (CPSE:NOVO B) access to evaluate NPM-139, a semaglutide implant for chronic weight management, offering investors another data point on the company’s obesity drug delivery options. See our latest analysis for Novo Nordisk. The Vivani agreement lands at a time when Novo Nordisk’s DKK323.15 share price has shown strong short term momentum, with a 30 day share price return of 18.81% and a 90 day share price return of 35.72%. Over longer periods,...

Detailed price information for Vivani Medical Inc (VANI-Q) from The Globe and Mail including charting and trades.

Tipranks Press Release.

Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani. ALAMEDA, Calif., July 07, 2026-- Vivani Medical, Inc., an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139,...